Phlox Therapeutics funding news – Naarden-based Phlox Therapeutics has Secured €1.9Million in Funding

This funding round brings ROM Utrecht Region into the group of investors, which already includes FIRST Fund, Amsterdam UMC Venture Holding, and Utrecht Health Seed Fund.

Phlox also received non-dilutive funding from the Dutch Research Council (NWO) and a partnership with the Hubrecht Institute, supported by Health~Holland, further strengthening the company’s financial resources.

What does Phlox Therapeutics offer?

Phlox Therapeutics, founded in 2022 by Yigal Pinto and Eva van Rooij, is working on RNA-based gene therapies to treat cardiomyopathies, which are heart muscle disorders.

The company aims to target genetic mutations linked to these conditions to improve outcomes for patients who have few treatment options with existing care methods.

Read more : Prelude funding news – Paris-based Prelude has Raised €7.6 Million in Seed Funding

With its focus on advancing RNA technology Phlox is positioning itself as a leader in developing next-generation therapies for genetic heart diseases.

Adinda Woelderink, Investment Manager at ROM Utrecht Region, says, “We are excited to support Phlox Therapeutics in its groundbreaking work developing RNA therapies for cardiomyopathies.Their approach to addressing currently untreatable genetic laminopathies holds great promise, and we believe this funding will play a critical role in driving their lead program further into preclinical development.”

Purpose of Fund Raising

Phlox Therapeutics has secured funding to support the early development of its main program, which focuses on genetic diseases linked to the lamin protein.

The mix of investment and non-dilutive funding will help Phlox advance its research and continue developing RNA therapies for genetic heart diseases.

Prof. Eva van Rooij, Phlox Therapeutics’ CSO, adds, “The Phlox’s team is delighted to have the support of this syndicate of investors. The public-private partnership with the Hubrecht Institute, combined with the additional support from Health~Holland, allows us to accelerate our preclinical work and simultaneously deepen our scientific understanding of cardio-myopathies. We are eager to move closer to clinical applications that could benefit patients with these life-threatening conditions.”

About Phlox Therapeutics

Phlox Therapeutics is developing gene therapies to treat and potentially cure heart muscle diseases. By exploring new ideas, they aim to improve the lives of patients who don’t have effective treatments, using RNA-based strategies to reduce the impact of harmful genetic mutations.